Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized dose-ranging study of gepotidacin for uncomplicated urogenital gonorrhea
2015-005120-26Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gepotidacin in gonorrhea (GC) (2 arms), sponsored by GSK. Primary endpoint: Culture-confirmed bacterial eradication of urogenital Neisseria gonorrhoeae at Test-of-Cure visit. Started Jan 2016; status: completed.
02
Drugs
gepotidacin
03
Conditions
gonorrhea (GC)
Beyond the preview
Go deeper on 2015-005120-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005120-26.